Of note, there is an ongoing phase Ib clinical trial assessing the safety and tolerability of neoadjuvant SBRT and tislelizumab, a PD-1 inhibitor, prior to hepatic resection in patients with resectable HCC (101). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.